- Home
- EBTC vs TERN Comparison
EBTC vs TERN Comparison
Compare EBTC & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBTC
- TERN
- Stock Information
- Founded
- EBTC 1989
- TERN 2017
- Country
- EBTC United States
- TERN United States
- Employees
- EBTC N/A
- TERN N/A
- Industry
- EBTC Major Banks
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- EBTC Finance
- TERN Health Care
- Exchange
- EBTC Nasdaq
- TERN Nasdaq
- Market Cap
- EBTC 455.5M
- TERN 499.4M
- IPO Year
- EBTC 2005
- TERN 2021
- Fundamental
- Price
- EBTC $41.72
- TERN $5.76
- Analyst Decision
- EBTC
- TERN Buy
- Analyst Count
- EBTC 0
- TERN 5
- Target Price
- EBTC N/A
- TERN $18.30
- AVG Volume (30 Days)
- EBTC 50.1K
- TERN 1.8M
- Earning Date
- EBTC 01-23-2025
- TERN 11-12-2024
- Dividend Yield
- EBTC 2.21%
- TERN N/A
- EPS Growth
- EBTC N/A
- TERN N/A
- EPS
- EBTC 2.91
- TERN N/A
- Revenue
- EBTC $164,115,000.00
- TERN N/A
- Revenue This Year
- EBTC N/A
- TERN N/A
- Revenue Next Year
- EBTC N/A
- TERN N/A
- P/E Ratio
- EBTC $14.94
- TERN N/A
- Revenue Growth
- EBTC N/A
- TERN N/A
- 52 Week Low
- EBTC $22.60
- TERN $4.32
- 52 Week High
- EBTC $44.08
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- EBTC 68.09
- TERN 48.82
- Support Level
- EBTC $42.13
- TERN $6.41
- Resistance Level
- EBTC $43.48
- TERN $7.14
- Average True Range (ATR)
- EBTC 1.24
- TERN 0.45
- MACD
- EBTC 0.30
- TERN 0.07
- Stochastic Oscillator
- EBTC 83.61
- TERN 40.27
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.